3 results
The primary objective is to determine if the addition of daratumumab to VRd will prolong PFS defined as the time from the date of randomization to the date of disease progression (assessed by International Myeloma Working Group [IMWG] criteria) or…
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.
The current proof-of-concept study has been designed to assess the efficacy and safety of the Peregrine Kit in the treatment of subjects with hypertension, when discontinued from their antihypertensive medications. This will be an *off medication*…